Boston Scientific Corp. Stock Plummets to New 52-Week Low of $48.13

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 48.13 on May 29, 2026. This decline reflects a challenging year for the company, with its stock price down 37.6% over the past year, contrasting sharply with the S&P 500's performance of 28.21% during the same period. As a large-cap player in the retailing industry, Boston Scientific Corp. holds a market capitalization of approximately USD 121.9 billion. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating how investors value its earnings relative to its stock price. Additionally, the company has a debt-to-equity ratio of 0.39, suggesting a moderate level of debt compared to its equity. Despite the current stock price challenges, Boston Scientific maintains a return on equity of 13.88% and a price-to-book ratio of 5.03. The absence of a dividend yield indicates a focus on reinvesting earnings back into the business. The stock's performance and financial metrics will be closely monitored as the company navigates its market position.